In Vitro and In Vivo Efficacy of the Triazole TAK-187 against Cryptococcus neoformans
AUTOR(ES)
Schell, Wiley A.
FONTE
American Society for Microbiology
RESUMO
Multiple isolates of Cryptococcus neoformans, including those with fluconazole resistance, were tested to assess the in vitro activity of the new triazole TAK-187. MICs of TAK-187 were at least eightfold lower than those of fluconazole, and fungicidal concentrations for most isolates were 4 μg/ml or less. TAK-187 also was evaluated as intermittent therapy using two dosages in a rabbit model of experimental cryptococcal meningitis. Compared to daily treatment with fluconazole, as little as two doses of TAK-187 given 7 days apart were found to be effective. Plasma and cerebrospinal fluid TAK-187 concentrations were many times higher than MICs and fungicidal concentrations. Based upon its therapeutic efficacy and long half-life in the rabbit model, TAK-187 should be investigated for intermittent dosing in treatment or suppression of cryptococcal infections in humans.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=105909Documentos Relacionados
- In Vitro and In Vivo Efficacies of the New Triazole Albaconazole against Cryptococcus neoformans
- In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
- In Vitro and In Vivo Activity of a Synthetic Halogenated Quinoline Against Cryptococcus neoformans
- In Vitro Comparative Efficacy of Voriconazole and Itraconazole against Fluconazole-Susceptible and -Resistant Cryptococcus neoformans Isolates
- In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.
